Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNF-a Antagonists in Post-cardiac Arrest Syndrome
NCT07176754Active, not recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Oct 2025
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, double-blind trial of infliximab in cardiac arrest (SCA) and post-cardiac arrest syndrome (PCAS) (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: 30-day survival rate. Started Oct 2025; status: active, not recruiting.
02
Drugs
infliximab
03
Conditions
cardiac arrest (SCA)post-cardiac arrest syndrome (PCAS)
Beyond the preview
Go deeper on NCT07176754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07176754.